Summit Therapeutics Inc. (SMMT)
| Previous close | 8.69 |
| Open | 9.84 |
| Bid | 8.75 x 500 |
| Ask | 9.24 x 500 |
| Day's range | 8.83 - 9.94 |
| 52-week range | 1.52 - 11.25 |
| Volume | |
| Avg. volume | 3,555,577 |
| Market cap | 6.328B |
| Beta (5Y monthly) | -1.13 |
| PE ratio (TTM) | 23.72 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Bloomberg
Summit Shares Soar After Cancer Drug Tops Merck’s Keytruda
(Bloomberg) -- Summit Therapeutics Inc. shares jumped after the biotech company said a late-stage trial met its goal in patients with non-small cell lung cancer.Most Read from BloombergDonald Trump Becomes First Former US President Guilty of CrimesSouth Africa Election Results With 29% Voting Districts InWall Street Billionaires Are Rushing to Back Trump, Verdict Be DamnedTrump Is Guilty on All Counts in Hush-Money Case. Now What?World’s Largest Nuclear Plant Sits Idle While Energy Needs SoarThe
- Barrons.com
Competitor to Merck's Keytruda Worries Some Investors
Investors in Merck don't seem pleased with a competitor cancer-treatment candidate outperforming Keytruda. Summit Therapeutics says its monotherapy ivonescimab outperformed pembrolizumab, sold under brand name Keytruda, in a Phase 3 trial involving lung-cancer patients.
- Insider Monkey
Summit Therapeutics Inc. (NASDAQ:SMMT) Q1 2024 Earnings Call Transcript
Summit Therapeutics Inc. (NASDAQ:SMMT) Q1 2024 Earnings Call Transcript May 1, 2024 Summit Therapeutics Inc. reports earnings inline with expectations. Reported EPS is $-0.06 EPS, expectations were $-0.06. SMMT isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good morning, ladies […]
